Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience announced the publication of a study in Cell Reports Medicine detailing the biomarker analysis from their OPTIMIZE-1 trial, which evaluated the CD40 agonist mitazalimab in combination with mFOLFIRINOX chemotherapy for metastatic pancreatic cancer. The study demonstrated significant clinical efficacy, with improved survival rates and immune activation linked to mitazalimab, supporting its further development and the use of predictive biomarkers to identify patients who may benefit most from this treatment.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company specializing in the development of clinical-stage tumor-directed antibody drugs, with a focus on the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients. The company’s lead drug candidate, mitazalimab, is progressing towards Phase 3 development and has shown promising survival data in metastatic pancreatic cancer trials. Alligator is listed on Nasdaq Stockholm and is based in Lund, Sweden.
Average Trading Volume: 509,340
Technical Sentiment Signal: Sell
Current Market Cap: SEK199.3M
For detailed information about ATORX stock, go to TipRanks’ Stock Analysis page.